PALM BEACH, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - One of the most common malignancies in the world today is gastric cancer. The incidence rate is influenced by various factors, including the aging of the population, dietary choices, lifestyle changes, and the prevalence of Helicobacter pylori infection. Growth in the market is driven by an increase in demand for diagnostic tools, therapies, and supporting care in tandem with a rise in the number of diagnosed cases. A recen ...

Bristol-Myers Squibb Company (NYSE:BMY) Citi’s 2024 Global Healthcare Conference December 3, 2024 8:00 AM ET Company Participants Christopher Boerner - CEO and Board Chair David Elkins - EVP and CFO Conference Call Participants Geoff Meacham - Citi Mary Kate Davis - Citi Geoff Meacham Welcome to the first session of the First Annual Global Healthcare Conference at Citi. We're thrilled to be here and we're thrilled to have with us. My name is Geoff Meacham. I'm the Senior Biopharma Analyst and we have Mary ...

Bristol-Myers Squibb (BMY -0.08%) is the kind of stock that potentially has a lot to offer to investors looking for wealth-building investments. With a large repertoire of medicines on the market, and a constant stream of programs approaching maturity and a shot at getting approved for sale, there's no question that the business will continue to create drugs that are in demand around the world.But solid companies don't always make for the perfect investments, especially when investors have outsized expectat ...

The sell-offs of these stocks were driven by issues that were never going to last.Finding attractive dividend stocks you can hold isn't too difficult. Finding dividend stocks you can comfortably buy and hold forever is a different story. For your truly long-term holdings, you'll want companies that are not only leading names with staying power, but that also operate in resilient markets -- a rarer set of criteria.Of course, if such a stock is on sale at the time you're ready to take the plunge, so much the ...

POLAND - 2024/11/22: In this photo illustration, the Bristol-Myers Squibb company logo is seen ... [+] displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesGiven its better prospects, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). BMY stock trades at 8.3x its forward expected earnings (2025), versus 14.7x for JNJ. However, ...

When I last wrote about the pharmaceuticals company Bristol-Myers Squibb Company (NYSE: BMY ) in August, I had given it a Sell rating for the short term. This was based on the likelihood of a price drop on the releaseManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group, Green Growth Gia ...

Generating thousands of dollars of recurring income can be a great way to make you less reliant on employment income or retirement benefits. If you have savings that you can afford to invest in stocks, there are multiple high-yielding dividend investments to consider right now. While many investors have been focusing on growth stocks and hype surrounding artificial intelligence, dividend stocks have been on the back burner of late, which could make now an advantageous time to invest in them.Three dividend s ...

Summary of Bristol-Myers Squibb Company Conference Call Company Overview - **Company**: Bristol-Myers Squibb Company (NYSE: BMY) - **Event**: Jefferies London Healthcare Conference - **Date**: November 19, 2024 - **Participants**: David Elkins (CFO), Unidentified Company Representative Key Points Industry and Company Performance - The focus for the year is on execution, with two strong quarters indicating a transformation within the company [2][11] - The growth portfolio has seen a **20% increase** in constant currency, now representing nearly **50%** of the company's revenue [3][12] - Legacy portfolio remains a significant cash generator for the business [2] Product Pipeline and Upcoming Approvals - **Cobenfy**: Recently acquired product with promising feedback from physicians; expected to be a multibillion-dollar product with multiple indications [3][6] - Upcoming **PDUFA date** for subcutaneous Opdivo in December, aimed at improving patient experience and reducing healthcare costs [4][29] - Strong growth in key products: - **Camzyos**: Cardiovascular drug for obstructive HCM, doubled sales compared to last year [5] - **Breyanzi**: Cell therapy for large B-cell lymphoma, also doubled sales [5] - **Reblozyl**: First-line MDS treatment, doubled sales [5] Future Growth and Clinical Trials - Multiple Phase III data readouts expected between now and 2026, including indications for schizophrenia and Alzheimer's disease [6][12] - **Milvexian**: Expansion of patient population with important Phase III studies planned for ACS and secondary stroke prevention [7][12] - Focus on driving efficiencies with a **$1.5 billion savings initiative** aimed at improving ROI and growth profile [9] Business Development Strategy - Significant business development activity with nearly **$30 billion** in acquisitions over recent years [14] - Current focus on integrating recent acquisitions and paying down **$10 billion** in debt by 2026 [15][14] - Future strategy includes smaller bolt-on acquisitions and collaborations once integration is complete [15] Market Position and Competitive Landscape - The company is well-positioned in therapeutic areas with high unmet medical needs, particularly in solid tumor oncology and neuro products [17][18] - Cobenfy is expected to address significant unmet needs in Alzheimer's disease and other indications, with potential for multibillion-dollar revenue [18][19] Regulatory Environment and Industry Resilience - The company remains confident in navigating regulatory changes and emphasizes the resilience of the healthcare industry [33] - Focus on delivering innovative medicines that address serious unmet medical needs while managing costs [33] Conclusion - Bristol-Myers Squibb is poised for growth with a strong pipeline, strategic focus on execution, and a commitment to addressing unmet medical needs in various therapeutic areas. The company is actively managing its business development strategy while preparing for significant product launches and clinical trial outcomes in the coming years [2][12][15].

On October 31, Bristol-Myers Squibb (NYSE: BMY ) released financial results for the third quarter of 2024 , which not only beat Wall Street analysts' expectations by a wide margin but also pleasantly surprised me.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceu ...

Core Insights - Bristol Myers Squibb (BMY) stock rose 10% following AbbVie's failure in mid-stage clinical trials for its schizophrenia drug Emraclidine, which enhances BMY's position after receiving FDA approval for its own schizophrenia drug, Cobenfy, expected to bring a 20% upside to BMY stock [1][6] Financial Performance - BMY stock has declined 11% since January 2023, from $67 to around $60, while the S&P 500 increased by 57% during the same period [2] - The company's price-to-sales (P/S) ratio fell by 15% to 2.6x, while revenue increased by 1% from $46 billion to $47 billion, and share count reduced by 4.1% due to $13 billion in share repurchases [2] Sales Growth Drivers - BMY's revenue growth has been limited to 1% since 2022, primarily due to declining sales of legacy drugs like Revlimid, while Eliquis generated over $12 billion in sales last year and is expected to continue growing [4][5] - New drugs such as Camzyos, Sotyktu, and Opdualag are projected to exceed $1 billion in sales each by 2026, and BMY has made three acquisitions to enhance its pipeline, now with over 50 compounds in development [5] Profit Margins - BMY's operating margin has contracted from 19.7% in 2022 to 15.3% currently, influenced by increased expenses related to research and development and acquisitions [7] - The company anticipates adjusted earnings per share for 2024 to be between $0.75 and $0.95, significantly lower than the $7.51 reported in 2023 due to a one-time charge of $12.1 billion for the acquisition of Karuna [7] Financial Risk Assessment - BMY's cash reserves decreased from $9.3 billion in 2022 to $8.1 billion, while total debt rose from $40.7 billion to $51.4 billion, indicating a high debt level but a reasonable financial risk profile [8] Stock Growth Potential - BMY stock has increased by 21% this year, underperforming the S&P 500's 26% rise, with historical volatility reflected in returns of 3% in 2021, 19% in 2022, and -26% in 2023 [9][10] - The current valuation of BMY stock at around $60, trading at 2.5x revenues, aligns with its average P/S ratio over the past three years, suggesting that the stock is appropriately priced given the mix of new drug opportunities and challenges from legacy drugs [10]